Medical Sciences, Indiana University School of Medicine, Indiana University School of Medicine, Jordan Hall 300, 1001 East Third Street, Bloomington, IN 47405, USA.
Adv Exp Med Biol. 2013;754:285-311. doi: 10.1007/978-1-4419-9967-2_14.
It is now well established that epigenetic aberrations occur early in malignant transformation, raising the possibility of identifying chemopreventive compounds or reliable diagnostic screening using epigenetic biomarkers. Combinatorial therapies effective for the reexpression of tumor suppressors, facilitating resensitization to conventional chemotherapies, hold great promise for the future therapy of cancer. This approach may also perturb cancer stem cells and thus represent an effective means for managing a number of solid tumors. We believe that in the near future, anticancer drug regimens will routinely include epigenetic therapies, possibly in conjunction with inhibitors of "stemness" signal pathways, to effectively reduce the devastating occurrence of cancer chemotherapy resistance.
现在已经证实，表观遗传异常在恶性转化的早期就会发生，这使得人们有可能利用表观遗传生物标志物来识别化学预防化合物或进行可靠的诊断筛查。对于重新表达肿瘤抑制因子的组合疗法，通过促进对传统化疗的重新敏感，为癌症的未来治疗带来了巨大的希望。这种方法也可能扰乱癌症干细胞，因此代表了一种有效管理多种实体肿瘤的手段。我们相信，在不久的将来，抗癌药物方案将常规包括表观遗传疗法，可能与“干性”信号通路抑制剂联合使用，以有效降低癌症化疗耐药性的破坏性发生。
